Cannabinoid-focused drugmaker InMed blames ‘recessionary pressures’ for exiting wellness sector

Jumping into the health and wellness sector once seemed like an easy win for some pharma companies, but the tough times are increasingly extending beyond biotech. That certainly seems to be the case for InMed Pharmaceuticals, which is backing out of the wellness arena less than a year after the Canadian drug developer acquired cannabinoid company BayMedica.

error: Content is protected !!